



Background: PAH BEI


- Adopted 2005
- 1-hydroxypyrene (1HP) marker of current choice
- NQ....with a benchmark (1ug/l)
- Data not strong enough to support TLV equivalent or to be based on health effects
- Adjustment provided for mixtures with different benzo(a)pyrene: pyrene ratios

Why 1HP?

- Pyrene is abundant in most PAH mixtures
- Physical behavior <u>approximates</u> 4+ ring PAHs
- ~85% metabolized to 1HP
- Compared to BAP....2.5 times more common, and many fewer metabolites
- Pyrene is non-carcinogenic...Is 3-OHBAP associated with risk or detoxification?








- Approaches
 - -Relate 1HP levels to clisease cases - Epidemiology Studies
 - -Relate 1HP levels to effect biomarkers
 - Molecular Epidemiology Studies




1HP and Disease IncidenceAre cancer incidence studies possible?


- What is the exposure window captured by 1HP?
- Half lives are 5.5, 23 and 384 hours
- Post shift 1HP measures the current day's exposure
- Pre-shift Monday 1HP estimates cumulative exposure
- Is there day to day exposure variability?



Can 1HP levels be related to Early/Reversible effect Biomarkers?

- Assumptions
 - 1HP levels predict total and carcinogenic PAH exposures
 - PAH exposures cause DNA adducts or other damage (e.g., chromosomal damage)
 - DNA adducts levels are related to disease risk







- Leukocytes in Blood
 - 8% monocytes + 25% lymphocytes+ 67% granulocytes
 - Granulocytes are in the blood for a few hours; short exposure window....
- Skin cells, monocyte/lymphocyte and exfoliated cell adducts are better correlated with exposure markers for PAH


Target Organ DNA Adducts and Cancer


- Supported by animal studies
 Beland
- Groopman studies in China
 Synergy between aflatoxin adducts and
 - Synergy between anatoxin adddcts an hepatitis B
- Veglia showed that adduct levels could be used categorically to predict lung cancer risk
- Studies in our lab with benzidine, tobacco smoke are similar


BENZIDINE IN CHINA

- Production stopped in 1977
- Bi, et al, 1992*
 - Overall a 25 fold excess risk
 - 4.8 fold excess in "low" group
 - 36.2 fold excess in "medium"
 - 158 fold excess in "high" exposure
- Hayes, et al, 1993** saw that acetylation phenotype did not affect risk

*Am. J. Ind. Med., 21,481-90. **Carcinogenesis, 14, 675-78.











Exposures in Dutch Rubberworks


- Documented decrease in total and specific dusts over the last 10 years
- Health effects (urinary bladder cancer) still elevated in latest reports for the industry












P values for type 3 tests of fixed effects of factory and department on biomarkers									
Model	Fixed Effect		Ċ						
	Ĩ Ø	1HP	Mutat.	Uro adds	WBC				
1	Factory	0.174	0.6874	8069.0	0.605				
2	Dept.	0.019	0.0582	0.0001	0.9136				
3	Factory	0.180	0.804	888.0	0.475				
2	Dept.	0.025	0.106	0.0016	0.728				
4 .	Factory	0.106	0.800	0.089	0.8512				
	Dept	0.010	0.336	0.0001	0.770				
a	FXD	0.004	0.930	0.0029	0.914				
D.		(32)	()						


Net 1HP (ug/I) and Production Function							
0,	Ν	GŅ 🌀	P value*				
Mixing	10	0.0	0.490				
Pre-treating	16	6.06	0.305				
Molding	<mark>28</mark>	0.14	0.06				
Curing	<mark>28</mark>	0.24	0.003				
Finishing	11	80.0	0.555				
Lab	2	0.0					
Shipping	4	0.06	.114				
*Paired t test (weekday-Sunda	5						


Association between 1HP, muU, UroAdds and WBC								
	Model	β (SE)	Р					
	1HP as predictor							
٢.	Urinary mutagenicity (muU)	0.18 (0.18)	0.315					
	Total Urothelial Adducts	1.4 (0.68)	0.035 (
	Adduct 1	0.41 (0.48)	0.387					
	Adduct 3	0.92 (0.49)	0.058					
	WBC Adducts	-0.8 (0.65)	0.217					
		BA CONTRACT						
	Predictor: Urinary mutagenicity							
	Total Urothelial Adducts	0.75 (0.34)	0.03					
	Adduct 1	0.59(0.29)	0.04					
	Adduct 3	0.35(0.26)	0.18					
	WBC Adducts	-0.58 (0.46)	0.20					



Summary of urothelial adduct/metabolite studies

- Benzidine exposure: adduct levels proportionate to metabolites and risk (aromatic amines)
- Active smoking: adduct levels proportionate to BC risk, 1 HP levels seem to underrepresent risk (aromatic amines?)





- Benzidine exposure: adduct levels proportionate to metabolites and risk (aromatic amines)
- Active smoking: adduct levels proportionate to BC risk, 1 HP levels seem to underrepresent risk (aromatic amines?)
- Passive smoking: adducts and 1HP levels not correlated....adducts 1.8X increased, risk ???

Questions....

- If adducts are increased in proportion to 1HP levels, can they be used as the effect level for increases in 1HP?
- Where do adduct levels above the population background become biologically significant with the object to protect worker health ?

Issues when using DNA adducts as risk estimates

- Between lab variability is large
- However, within lab variability is much better especially relative to controls....there was no control group in our rubber workers study which limits the conclusions that can be drawn.

Health Based BEI for PAH

- Will not likely be set on one effect biomarker, or on a single measurement of internal dose
- A web of evidence along the causal pathway is needed including DNA adducts, chromosome damage, DNA fragmentation and other tests in studies which include multiple measurements of external exposure and internal dose.



